Botulism Clinical Trial
Official title:
A Phase 3, Double Blind, Placebo Controlled, Randomized, Multicenter Clinical Trial to Demonstrate the Safety, Lot Consistency and Clinical Benefit of Recombinant Botulinum Vaccine A/B (rBV A/B)
This Phase 3 clinical trial is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B in male and female healthy adults 18 to 55 years of age.
Currently, there are no licensed vaccines or pre-exposure prophylactic medical countermeasures available to provide protection against botulism. The rBV A/B is under development to provide protection of adults 18 to 55 years of age from fatal botulism caused by inhalational intoxication with botulinum neurotoxin complex (BoNT) serotype A, subtype A1 (BoNT/A1) and botulinum neurotoxin complex serotype B, subtype B1 (BoNT/B1). Volunteers will not be exposed to botulism. Protective antibody titers will be measured in serum after vaccination. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03603665 -
A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT04550793 -
Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
|
||
Completed |
NCT01441557 -
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
|
Phase 2/Phase 3 | |
Recruiting |
NCT05769478 -
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
|
Phase 1 | |
Enrolling by invitation |
NCT02051062 -
BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
|
Phase 4 | |
Completed |
NCT02055183 -
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
|
||
Completed |
NCT01357213 -
Phase 1 PK Study of XOMA 3AB
|
Phase 1 | |
Completed |
NCT03676634 -
Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
Completed |
NCT00314080 -
Treatment of Survivors After Botulism Outbreak
|
N/A | |
Not yet recruiting |
NCT06112834 -
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
Completed |
NCT00348426 -
Botulism Outbreak in Thailand (Episode II)
|
Phase 4 | |
Completed |
NCT00004401 -
Study of Human Botulism Immunoglobulin in Infants With Botulism
|
N/A | |
Completed |
NCT01701999 -
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
|
Phase 2 | |
Completed |
NCT02779140 -
Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
|
Phase 1 |